| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
NextCure, Inc.$2.18
+0.21 (+10.66%)
D 37Pipeline Score Overvalued Pharma · Clinical
Market Cap
28.28 M
EPS
-19.07
P/E Ratio
-
Value Trade
450.68 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
6.83 M
Operating CF
-13.36 M
Total Assets
37.98 M
Total Liabilities
11.26 M
Equity
26.72 M
D/E Ratio
12,345
-20.87 %
Week
-28.1 %
1 Month
-43.55 %
3 Month
-17.06 %
6 Month
-92.15 %
5 Year
-95.8 %
All Time
Cash Data
Cash Position
29.74 M
Monthly Burn
4.45 M
Runway
4.5 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
222.98 K
52 Week Range
4.60 - 15.74
% held by Insiders
34.28 %
% held by Institutions
49.8 %
Enterprise Value
3.46 M
Total Shares
3.61 M
Short %
6.69 %
Float Shares
2.51 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NextCure, Inc.
287Total events
4Upcoming
50Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆IND SubmissionNC605IND
Subscribe to view catalyst details
TBD
◆Enrollment UpdateSIM0505Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-06-02 | LNCB74 (B7-H4 targeted antibody-drug conjugate) | phase 1 data readout | Phase 1 | — | – | – | – |
2025-06-02 | LNCB74 (B7-H4 targeted antibody-drug conjugate) | phase 1 data readout | Phase 1 | — | – | – | – |
2025-06-02 | LNCB74 (B7-H4 targeted antibody-drug conjugate) | phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D37
Pipeline Score $17M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.6x
rNPV / MCap Top 51%
Micro Cap (rank 448 of 912)
Percentile RankNextCure, Inc. faces pipeline headwinds (37/100), with $1.9B risk-adjusted pipeline value, led by NC318 in Advanced or Metastatic Solid Tumors (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NC318 Small molecule | Advanced Non-small Cell Lung Cancer | Phase 2 | NCT04699123 | 10% | $941M | ACTIVE NOT_RECRUITING | 159 | - | - | Jun 30, 2025 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SIM0505 Fast Track | gynecologic cancers | Phase 1 | 2026-06-01 | In a Phase 1 trial of SIM0505 for gynecologic cancers, the drug demonstrated a 55% overall response rate (ORR) at 12 weeks, with 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma, within a therapeutic dose range of 4.8 – 8.0 mg/kg. Read More | NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 Read More | |
SIM0505 Fast Track | gynecologic cancers | Phase 1 | 2026-06-01 | In a Phase 1 trial of SIM0505 for gynecologic cancers, the drug demonstrated a 55% overall response rate (ORR) at 12 weeks, with 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma, within a therapeutic dose range of 4.8 – 8.0 mg/kg. Read More | NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 Read More | |
SIM0505 Fast Track | gynecologic cancers | Phase 1 | 2026-06-01 | In a Phase 1 trial of SIM0505 for gynecologic cancers, the drug demonstrated a 55% overall response rate (ORR) at 12 weeks, with 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma, within a therapeutic dose range of 4.8 – 8.0 mg/kg. Read More | NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NXTC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NXTC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NXTC▼ -45.5%on this news
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
NextCure presented promising Phase 1 data for SIM0505 at ASCO 2026, showing a 55% objective response rate in gynecologic cancers, including 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma. The therapy demonstrated a favorable safety profile in heavily pretreated patients. NextCure plans to continue dose optimization and will host a virtual KOL event to discuss these results.
Read more →NXTC▼ -5%on this news
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
NextCure, Inc. reported a business update and financial results for Q1 2026, highlighting the Fast Track designation for SIM0505 in treating platinum-resistant ovarian cancer. The company plans to present Phase 1 data at ASCO 2026 and has initiated a dose optimization study. Despite a net loss of $9.8 million, NextCure aims to expand its trial sites into Canada and Europe.
Read more →NXTCNextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
NextCure and Simcere Zaiming have initiated the dose optimization phase of their Phase 1 study for SIM0505, targeting platinum-resistant ovarian cancer. The investigational ADC aims to finalize dose selection and expand its clinical footprint. Phase 1 data is expected to be presented at ASCO 2026, highlighting the development progress.
Read more →NXTC▼ -6.2%on this news
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
NextCure has announced that Phase 1 data for SIM0505, an investigational antibody drug conjugate targeting CDH6, will be presented at ASCO 2026. This presentation signifies an important milestone in NextCure's collaborative clinical approach and commitment to developing innovative cancer therapies. SIM0505 is currently being evaluated for its effectiveness in treating advanced solid tumors, including platinum-resistant ovarian cancer. The presentation is scheduled for June 1, 2026, in Chicago, Illinois.
Read more →NXTCNextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
NextCure, Inc. has received Fast Track designation from the FDA for SIM0505, an investigational antibody drug conjugate aimed at treating platinum-resistant ovarian cancer. This designation will facilitate closer collaboration with the FDA, expediting the development process. The company plans to initiate dose optimization in Q2 2026 and present Phase 1 data at the ASCO conference in 2026.
Read more →NXTCNextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
NextCure, Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. have announced that an abstract for their investigational antibody drug conjugate, SIM0505, has been accepted for presentation at the ASCO 2026 meeting. The ongoing Phase 1 study is focused on advanced solid tumors, particularly platinum-resistant ovarian cancer. This development highlights the potential of SIM0505 in cancer treatment.
Read more →NXTCNextCure Provides Business Update and Reports Full Year 2025 Financial Results - Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated
NextCure, Inc. has announced its business update and 2025 financial results, highlighting its expectations for a transformative 2026 driven by advancements in its SIM0505 program. The company aims to present dose escalation data from a Phase 1 trial and is set to enroll patients for a new study focusing on platinum-resistant ovarian cancer. Despite positive advancements, NextCure faces financial challenges, including a reported net loss and dependency on funding. The development of its antibody-drug conjugates demonstrates potential for impactful cancer therapies amid a backdrop of financial stringency.
Read more →NXTCNextCure Provides Business Update
NextCure, Inc. has provided a business update on its two antibody drug conjugate (ADC) programs, SIM0505 and LNCB74. SIM0505 is expected to have Phase 1 dose escalation data available in Q2 2026, while LNCB74 is currently undergoing Phase 1 trials. The company also reported its preliminary cash position for year-end 2025.
Read more →NXTC▼ -5.8%on this newsshared move
NextCure Provides Business Update - SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026 - LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, MD
NextCure, Inc. has provided a business update highlighting its antibody drug conjugate programs, particularly SIM0505 and LNCB74. The company anticipates Phase 1 dose escalation data for SIM0505 in Q2 2026, while LNCB74's studies are ongoing. NextCure maintains a cash position that is crucial for supporting its continued operations and development efforts. Forward-looking statements indicate potential risks related to clinical trials and the company's financial health.
Read more →NXTCNextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
NextCure, Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3rd. The event will be held in New York City and will include a live audio webcast available on their website. NextCure focuses on developing innovative cancer therapies, particularly for patients who do not respond to existing treatments.
Read more →NXTCNextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts - Extends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept ("POC")
NextCure, Inc. has successfully closed a $21.5 million private placement in public equity (PIPE), primarily led by several healthcare-focused funds. This financing is intended to bolster NextCure's working capital and ensures that the company's cash runway extends into the first half of 2027, beyond the expected data readouts from their antibody drug conjugate programs in the first half of 2026. The PIPE offering included the issuance of common stock and pre-funded warrants, with H.C. Wainwright & Co. serving as the exclusive placement agent.
Read more →NXTC▲ +9%on this news· ran to +19% by day 3shared move
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
NextCure, Inc. has announced a private placement of common stock, raising approximately $21.5 million. The offering, priced at $8.52 per share, involves institutional investors and is expected to close on November 13, 2025. The funds will be used for general working capital and to support ongoing clinical programs, extending the company's cash runway into the first half of 2027.
Read more →NXTCNextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
NextCure, Inc. has provided a business update and reported its financial results for Q3 2025. The company is advancing its antibody-drug conjugate (ADC) programs, including the initiation of a Phase 1 trial for SIM0505 in the U.S. and receiving FDA clearance for LNCB74's protocol amendment. NextCure expects to share proof of concept data for both therapies in the first half of 2026.
Read more →NXTC▲ +27.8%on this news· ran to +75% by day 1
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
NextCure, Inc. and Simcere Zaiming have announced the dosing of the first patient in the U.S. as part of the ongoing Phase 1 trial of SIM0505, an antibody drug conjugate targeting advanced solid tumors. The trial, initially launched in China, is now expanding to include U.S. patients, with promising safety and efficacy data reported. The companies aim to present proof-of-concept data in the first half of 2026.
Read more →NXTCNextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NextCure, Inc. will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8th, 2025. The event will be accessible via a live audio webcast on the company's website. NextCure is dedicated to developing innovative therapies for cancer patients who do not respond to existing treatments.
Read more →NXTCNextCure Provides Business Update and Reports Second Quarter 2025 Financial Results - Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patie
NextCure, Inc. (NXTC) announced a business update alongside its Q2 2025 financial results, highlighting a strategic partnership with Simcere Zaiming for the Phase 1 study of SIM0505. The company is set to dose its first patient using SIM0505 this quarter and aims to present updates and proof of concept data by mid-2026. Despite these advancements, NextCure continues to face significant financial losses and operational risks associated with its ongoing clinical developments.
Read more →NXTC▲ +17.3%on this news
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
NextCure, Inc. has presented promising preclinical data for NC605, an anti-Siglec-15 antibody, at the Brittle Bone Society Meeting. The data indicates that NC605 improves bone microarchitecture and reduces fracture incidence in a mouse model of osteogenesis imperfecta (OI) compared to anti-sclerostin treatment. This novel therapy could offer significant benefits for patients suffering from this rare bone disorder.
Read more →NXTC▼ -26.3%on this news
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
NextCure and Simcere Zaiming have announced a strategic partnership to develop SIM0505, a novel antibody-drug conjugate targeting CDH6 for solid tumors. Currently in Phase 1 trials in China, NextCure plans to initiate U.S. clinical testing in Q3 2025. The partnership also includes licensing agreements for additional ADC development.
Read more →NXTCNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
NextCure, Inc. and LigaChem Biosciences announced the presentation of a trial in progress poster for LNCB74, a B7-H4 targeted antibody-drug conjugate, at the ASCO Annual Meeting. The Phase 1 study evaluates LNCB74 as a monotherapy for patients with advanced solid tumors. The trial is currently in the dose escalation phase, focusing on various cancer types.
Read more →NXTCNextCure Provides Business Update and Reports First Quarter 2025 Financial Results - Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half
NextCure, Inc. reported its first quarter 2025 financial results and provided a business update. The company is advancing its LNCB74 antibody-drug conjugate program, having completed cohort 2 and planning to initiate backfill cohorts by H2 2025. Despite a significant net loss and a limited operating history, NextCure is focused on developing innovative cancer therapies, with future data readouts expected in 2026.
Read more →NXTC▼ -7.7%on this news
Corporate Presentation NASDAQ: NXTC APRIL 2025 Forward-Looking Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking s
NextCure is advancing its innovative cancer therapy LNCB74, an anti-B7-H4 antibody-drug conjugate, aimed at treating breast, endometrial, and ovarian cancers. The company has initiated a Phase 1 clinical trial and expects to report initial data in the second half of 2025. With a current balance sheet of approximately $68 million, NextCure is strategically positioned to progress this therapy, which utilizes a differentiated linker technology to enhance safety and efficacy. The therapy is targeting a critical unmet need in oncology.
Read more →NXTCNextCure to Present at 24th Annual Needham Virtual Healthcare Conference
NextCure, Inc. will present at the 24th Annual Needham Virtual Healthcare Conference on April 10th at 8:45 am ET. The presentation will focus on the company's innovative cancer therapies. A live audio webcast will be available, and a replay will be archived for 30 days. The company emphasizes its commitment to developing novel treatments for patients unresponsive to current therapies.
Read more →NXTCNextCure Provides Business Update and Reports Full Year 2024 Financial Results - Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in
NextCure, Inc. has provided a business update, highlighting the completion of cohort 1 of the Phase 1 trial for LNCB74, an antibody-drug conjugate aimed at treating multiple cancers. The company plans to initiate backfill cohorts later in 2025, suggesting ongoing development efforts. However, they also reported a net loss of $55,654 for 2024, indicating financial challenges and a continued need for funding. The update suggests a strategic focus on cancer treatments while acknowledging inherent risks in their operations.
Read more →NXTC▼ -6.1%on this news
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers BELTSVILLE, Md. - January 10 , 2025 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biophar
NextCure, Inc. has announced that the first patient has been dosed in its Phase 1 study of LNCB74, an antibody-drug conjugate targeting B7-H4 for multiple cancers. This event marks a significant milestone for the company as it advances its clinical development program. The company aims to establish the safety and preliminary efficacy of LNCB74, which received FDA approval for its Investigational New Drug application in December 2024. The drug is being developed in collaboration with LigaChem Biosciences.
Read more →NXTCNextCure Announces Acceptance of IND Application for LNCB74 - LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences BELTSVILLE, Md. - December 1
NextCure, Inc. has announced that the FDA has accepted its IND application for LNCB74, a B7-H4-targeting antibody-drug conjugate aimed at treating multiple cancers. This marks a major milestone for the company as they move forward into a Phase 1 clinical trial. The IND application is based on preclinical data suggesting LNCB74's unique potential. NextCure is collaborating with LigaChem Biosciences for the development of this therapeutic.
Read more →NXTC▼ -5.2%on this newsshared move
Corporate Presentation NASDAQ: NXTC DECEMBER 2024 Forward-Looking Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-lookin
NextCure has announced the progress of LNCB74, an antibody-drug conjugate targeting B7-H4 for the treatment of breast, ovarian, and endometrial cancers. The company reported a favorable safety and tolerability profile, with the IND for a Phase 1 trial submitted and initiation expected in early 2025. The trial will explore different dose requirements and safety endpoints over 65 subjects. Despite this, the company acknowledges risks related to forward-looking statements and potential disruptions from the COVID-19 pandemic.
Read more →NXTCNextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure, Inc. announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City on December 5, 2024. The company will feature in a fireside chat that aims to inform investors and stakeholders about its developments in cancer therapies. A live audio webcast will be available, along with a replay for 30 days post-event. NextCure is dedicated to advancing novel therapies for cancer patients who do not respond to existing treatments.
Read more →NXTCCorporate Presentation NASDAQ: NXTC NOVEMBER 2024 Forward-Looking Statement 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-lookin
NextCure is advancing its therapeutic candidate LNCB74, an antibody-drug conjugate targeting B7-H4, with an IND submission expected by Q4 2024. The company reported a favorable safety and tolerability profile from its preclinical studies, indicating readiness for a Phase 1 trial. There is a significant opportunity in the unmet needs regarding breast, endometrial, and ovarian cancers. However, forward-looking statements highlight inherent risks, including the unpredictable nature of clinical trial outcomes.
Read more →NXTCNextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-end - Cash of approximately $75 million expe
NextCure, Inc. provided a business update and reported its financial results for Q3 2024, emphasizing a shift in focus towards the development of LNCB74, a B7-H4 ADC, with plans to file an IND by year-end. The upcoming SITC presentation aims to showcase preclinical data that outlines LNCB74's differentiation from competing therapies. Furthermore, while the NC410 combo demonstrated promising results in clinical activities, NextCure intends to conclude ongoing trials and seek external partnerships to further the program. The company's financial performance reflected significant operational losses amid ongoing development efforts.
Read more →NXTCNextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
NextCure, Inc. reported promising preclinical data for its LNCB74 antibody-drug conjugate targeting B7-H4 and indicated plans to file for an Investigational New Drug application by the end of the year. Additionally, the company provided positive updates on its NC410 combination therapy with pembrolizumab for colorectal cancer patients. Clinical data revealed substantial disease control rates among patients treated, enhancing the potential of NC410 in previously unresponsive tumor types. The findings will be showcased at the Society for Immunotherapy of Cancer annual meeting.
Read more →NXTCNextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
NextCure, a clinical-stage biopharmaceutical firm, announced it will present findings at the upcoming Society for Immunotherapy of Cancer annual meeting in Houston, Texas, from November 6-10, 2024. The presentations will focus on pre-clinical data for LNCB74, an antibody-drug conjugate, and biomarker data from the NC410 combination study with pembrolizumab. These presentations aim to showcase NextCure's innovative approaches to treating cancer patients who have not responded to existing therapies.
Read more →NXTC▼ -5%on this news
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
NextCure, Inc. presented promising clinical data from the Phase 1b study of NC410 combined with pembrolizumab at ESMO 2024. The trial included patients with ovarian cancer and microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer, revealing clinical activity and durability in responses. The results suggest the treatment could offer benefits in addressing these hard-to-treat cancers. NextCure plans to continue tracking the progress of study participants and will provide further updates later this year.
Read more →NXTCNextCure Provides Business Update and Reports Second Quarter 2024 Financial Results - LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-end - NC410 combo with pembrolizumab ovarian coh
NextCure, Inc. has provided a business update and reported its financial results for the second quarter of 2024. The company has completed GLP toxicology studies for its B7-H4 ADC program, LNCB74, and is preparing to submit an IND application by the end of the year. Additionally, NextCure announced the completion of enrollment for additional ovarian cancer patients in the NC410 and pembrolizumab combination study and plans to share results from this expanded cohort later in the year. Despite a net loss reported, the company remains well-capitalized to fund its operations into the second half of 2026.
Read more →NXTC▲ +13.6%on this news· ran to +29% by day 3
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NextCure, Inc. is set to present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. The company will also host meetings with institutional investors during the event. NextCure focuses on developing innovative therapies for cancer and Alzheimer's disease. A recording of the presentation will be available on their website for 30 days following the event. The company has noted its limited operating history and significant financial challenges as part of its forward-looking statements.
Read more →NXTCNextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
NextCure, Inc. has announced promising Phase 1b data for NC410 in combination with pembrolizumab, to be presented at ASCO 2024. The clinical study showed a disease control rate of 51% in ICI-naïve colorectal cancer patients and 43% in ovarian cancer patients, indicating significant potential for these challenging conditions. Partial responses were noted in some patients, with manageable adverse events reported. NextCure's ongoing research aims to further explore the efficacy of this combination in the targeted patient populations.
Read more →NXTC▲ +8.8%on this news
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results - Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 - Presented preclinical data from LNCB74 (B7
NextCure, Inc. has provided a business update and reported its financial results for Q1 2024. The company anticipates presenting data from its NC410 combination trial at the upcoming ASCO Annual Meeting, alongside the advancement of its LNCB74 B7-H4 ADC program towards an IND submission by the end of the year. Despite these advancements, NextCure continues to face risks, including significant operational losses and challenges associated with clinical development and commercialization.
Read more →NXTC▼ -5.9%on this news· ran to -24% by day 3
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
NextCure, Inc. has announced a presentation of Phase 1b clinical trial data for NC410 in combination with pembrolizumab at the ASCO Annual Meeting in June 2024. The study focuses on patients with microsatellite stable colorectal cancer and ovarian cancer. This presentation is part of NextCure's ongoing efforts to develop innovative cancer therapies aimed at patients who do not respond to existing treatments. The clinical trial is an important step in assessing the efficacy of NC410 as a potential treatment option.
Read more →NXTC▼ -6%on this news
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
NextCure, Inc. has presented new preclinical data on LNCB74, a B7-H4-targeting ADC developed with LigaChem Biosciences, at the AACR 2024. The findings highlight LNCB74's potent cytotoxicity against B7-H4-expressing cancer cells and its strong anti-tumor activity in various preclinical models. Additionally, the ADC displayed superior tolerability and pharmacokinetics, suggesting a favorable safety profile compared to traditional ADCs. NextCure aims to build a robust preclinical dataset to advance LNCB74 into clinical trials.
Read more →NXTC▼ -10%on this news· ran to -21% by day 3shared move
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
NextCure, Inc. has appointed Dr. Rakesh Dixit to its Scientific Advisory Board to leverage his expertise in antibody-drug conjugates (ADCs). Dr. Dixit is a seasoned professional with over 30 years of experience in biotechnology, contributing to several successful biotherapeutics. His role will focus on advancing NextCure's proprietary ADCs, particularly LNCB74 targeting B7-H4. This appointment is expected to bolster NextCure's innovative capabilities in cancer treatment development.
Read more →NXTC▲ +7.8%on this newsshared move
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
NextCure, Inc. (NASDAQ: NXTC) announced its participation in the 23rd Annual Needham Virtual Healthcare Conference, scheduled for April 11th. The presentation aims to showcase NextCure's commitment to developing novel cancer therapies. Interested parties can access a live audio webcast through the company's website, which will also feature a replay of the presentation for 30 days post-event. The company highlights its innovative approach to treating patients who do not respond to current therapies.
Read more →NXTC▲ +19.1%on this news· ran to +40% by day 3
NextCure Provides Business Update and Reports Full Year 2023 Financial Results - Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC) - Based on early evidence of clinic
NextCure, Inc. has provided a business update and reported its financial results for the full year 2023, emphasizing a shift in focus towards its promising programs NC410 and LNCB74. The company plans to prioritize these candidates due to encouraging clinical data, particularly in treating ovarian and colorectal cancers. NextCure is currently working on partnering other assets while managing a restructuring of its workforce and operations. Keeping a solid cash position until mid-2026 is vital for advancing its clinical milestones.
Read more →NXTCNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
NextCure, Inc. announced the publication of preclinical data in Science Advances detailing the FLRT3-UNC5B pathway's role in T cell inhibition. The results indicate that FLRT3 functions as a checkpoint inhibitor, potentially allowing cancer cells to evade T cell activity. The study suggests that targeting FLRT3 with a monoclonal antibody may enhance the efficacy of existing immunotherapies, particularly for patients unresponsive to current treatments. Future studies will further explore FLRT3's effects on T cell signaling and cancer therapy development.
Read more →NXTCNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
NextCure, Inc. revealed preclinical data on a new monoclonal antibody targeting VSTM-1, aimed at treating progressive inflammatory airway disorders like COPD. This agonist antibody demonstrated effectiveness in reducing neutrophil-mediated inflammation and pulmonary pathology in animal models. The data was presented at the Keystone Symposium, highlighting NextCure's commitment to expanding its focus beyond oncology into chronic inflammatory diseases. The findings suggest a potential new standard of care in treating COPD and similar conditions, though the company acknowledges the inherent risks in clinical development.
Read more →NXTCNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
NextCure, Inc. announced the publication of research demonstrating that its anti-Siglec-15 antibody, NC605, effectively prevents bone loss due to immobilization following acute spinal cord injuries in animal models. The study showcased NC605's ability to inhibit bone resorption while promoting osteoblast recruitment, thus improving overall bone quality. This innovative approach addresses a critical clinical need, especially for patients suffering from severe immobilization, offering hope for better therapeutic options. The data were published in JMBR Plus and resulted from collaboration with notable research institutions.
Read more →NXTC▼ -19.3%on this news
NextCure Provides Year-End Clinical Pipeline Updates BELTSVILLE, Md.
NextCure, Inc. has announced year-end updates regarding its clinical pipeline, highlighting the development of its immunomedicines designed to treat cancer and other immune-related diseases. The company focuses on providing new treatment options for patients who do not respond well to existing therapies. However, it acknowledges various risks associated with clinical development and the uncertainty of future results. NextCure also faces challenges related to financing and maintaining a successful operational strategy.
Read more →NXTCNextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
NextCure, a clinical-stage biopharmaceutical company, will participate in the 35th Annual Piper Sandler Healthcare Conference in New York City on November 30th. The event will feature a fireside chat that aims to discuss the company's progress in developing novel immunomedicines targeting cancer and immune-related diseases. A live audio webcast of the chat will be available for interested investors, with a replay accessible for 30 days post-event. Despite its innovative approach, NextCure faces various challenges, including market entry risks and financial difficulties.
Read more →NXTC▲ +5.9%on this newsshared move
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
NextCure, Inc. announced a publication in the Journal of Clinical Investigation detailing the mechanism of action for NC525, a novel LAIR-1 antibody targeting acute myeloid leukemia (AML). The study indicates that NC525 can selectively induce cell death in leukemic stem cells while preserving healthy hematopoietic stem cells. The Phase 1 clinical trial is ongoing, with an update expected in Q4 2023. The findings suggest NC525 may effectively treat patients with resistant forms of AML, particularly when used in combination with existing therapies like ventoclax and azacytidine.
Read more →NXTC▲ +9.3%on this news
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results - Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year end - Cash of approximately $118 m
NextCure, Inc. has released its third quarter 2023 financial results and provided business updates, highlighting its plans for upcoming clinical program updates by year-end. The company reports a cash position of approximately $118 million, which is expected to support the advancement of several promising immunomedicine candidates. However, it continues to face substantial net losses and has not yet received approval for any products. Overall, while there are optimistic developments on the horizon, financial uncertainties persist.
Read more →NXTCNextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
NextCure has presented promising preclinical data for NC181, a novel therapeutic candidate targeting ApoE4, at the Neurodegeneration Targets Conference in Boston. The findings indicate that NC181 may assist in amyloid clearance, prevention of amyloid deposition, and normalization of neuroinflammation. The results suggest a differentiation from existing amyloid-targeted therapies, highlighting NC181's potential for treating conditions associated with Alzheimer's disease and cerebral amyloid angiopathy. Further studies on NC181's therapeutic efficacy are currently underway.
Read more →NXTCNextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
NextCure, Inc. has announced the publication of a review article in Frontiers in Immunology focusing on the regulation of tumor immunity by tumor collagen in the extracellular matrix. The article highlights the need to target tumor collagen to enhance anti-tumor immunity, underscoring its role in immune cell modulation within the tumor microenvironment. This research aims to contribute to the development of new therapeutics, particularly for patients who do not respond to existing therapies. Additionally, their immunomedicine NC410 shows promise in countering immune suppression and improving T cell function.
Read more →NXTCNextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NextCure, Inc. (Nasdaq: NXTC) will participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 11th in New York City. During this event, they will engage in a fireside chat which will be available via live audio webcast. The company's proprietary FIND-IO platform aims to discover new immunomedicines for cancer treatment, particularly for patients unresponsive to current therapies. NextCure's participation in industry events underscores its commitment to advancing its investigational immunomedicines despite facing financial and operational challenges.
Read more →NXTCNextCure Provides Business Update and Reports Second Quarter 2023 Financial Results - Phase 1b data for NC410 and further updates on other clinical programs expected in the fourth quarter of 2023 - Cash of approximately
NextCure, Inc. has released a business update alongside its second quarter 2023 financial results. The company is poised to present updates on its clinical programs in the fourth quarter. Despite significant advances in its research efforts, NextCure disclosed a net loss, reflecting ongoing financial challenges. The management emphasizes prudent resource management to ensure financial stability through mid-2025.
Read more →NXTCNextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
NextCure, Inc. presented promising non-clinical data on NC525, a humanized monoclonal antibody, at the 2023 FOCIS annual meeting. The data showcased NC525's mechanism of inducing apoptosis specifically in leukemic cells while preserving healthy hematopoietic cells. This suggests NC525 could potentially provide a targeted treatment option for patients with advanced myeloid leukemias. The company plans to provide an update on the ongoing clinical trial in the fourth quarter of 2023.
Read more →NXTC▲ +7.4%on this news
NextCure to Present at the JMP Securities Life Sciences Conference
NextCure, Inc. announced its participation in the JMP Securities Life Sciences Conference scheduled for May 16, 2023. The presentation will focus on the company's efforts in developing novel immunomedicines targeting cancer and other immune-related diseases. The event will include a live audio webcast available on NextCure's website, with replays accessible for 30 days post-conference. Additionally, the company acknowledges certain risks related to its operational history and financial status.
Read more →NXTCNextCure Provides Business Update and Reports First Quarter 2023 Financial Results - Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs - First patient dosed with NC525 (LAIR-1 mAb) in a Phase 1
NextCure, Inc. has provided a business update alongside its Q1 2023 financial results. The company anticipates upcoming clinical data readouts for its three major programs in 2023, emphasizing its commitment to developing innovative cancer treatments. CEO Michael Richman expressed confidence in the company's financial sustainability, expecting a runway of over two years to achieve significant clinical milestones. Despite these positive aspects, the company faces challenges, including historical losses and a lack of approved products for market sale.
Read more →NXTCNextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
NextCure, Inc. announced its participation in the 22nd Annual Needham Virtual Healthcare Conference scheduled for April 19th at 10:15 am ET. The presentation will be accessible through a live audio webcast on the company's website. NextCure focuses on developing novel immunomedicines using its proprietary FIND-IO platform, targeting cancer and other immune-related diseases. The company highlights its commitment to patients who do not respond to current therapies. However, several risks related to financing and clinical approvals remain.
Read more →NXTCNextCure Provides Business Update and Reports Full Year 2022 Financial Results - Clinical data updates expected in 2023 for all three programs - NC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid
NextCure, Inc. reported its full year 2022 financial results and provided a business update, indicating an optimistic outlook for 2023. The company is poised to release data updates on three clinical programs, backed by a substantial cash position. However, it faced a net loss increase over the previous year and continues to navigate risks related to clinical development and financial sustainability.
Read more →NXTCNextCure to Present at SVB Securities Global Biopharma Conference
NextCure, Inc. will present at the SVB Securities Global Biopharma Conference on February 15, 2023. The clinical-stage biopharmaceutical company is dedicated to discovering novel immunomedicines for cancer and related diseases. A live audio webcast of the presentation will be available, along with a replay accessible for 30 days. However, the company faces significant challenges including a limited history, financial losses, and the uncertainty of its clinical development path.
Read more →NXTCNextCure to Present at Upcoming Investor Conferences
BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCNextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
BELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC)
Read more →NXTC▼ -13.6%on this news
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clini
Read more →NXTCNextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
BELTSVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clini
Read more →NXTCNextCure Provides Update and Reports Third Quarter 2022 Financial Results - Discontinuing development of our NC318 program - Advancing clinical pipeline: NC410 combination, NC525, and NC762 - Extending runway into mid-20
NextCure Provides Update and Reports Third Quarter 2022 Financial Results BELTSVILLE, Md. - November 3, 2022 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
Read more →NXTCNextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appoin
Read more →NXTC▼ -12.6%on this news· ran to -24% by day 3
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
BELTSVILLE, Md., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it w
Read more →NXTCNextCure Provides Business Update and Reports Second Quarter 2022 Financial Results - On track to report data from all three clinical programs - Second quarter ending cash of $185.5 million expected to fund operations in
NextCure Provides Business Update and Reports Md. - August 4, 2022 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
Read more →NXTCNextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
BELTSVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the public
Read more →NXTCNextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, presented in vivo data at
Read more →NXTCNextCure Provides Business Update and Reports First Quarter 2022 Financial Results - On track to report data from all three clinical programs in the second half of 2022 - First quarter ending cash of $201.3 million expec
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results BELTSVILLE, Md. - May 5, 2022 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat
Read more →NXTCNextCure to Present at the BofA Securities 2022 Healthcare Conference
BELTSVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wil
Read more →NXTCNextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation
BELTSVILLE, Md., April 19, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publi
Read more →NXTCNextCure to Present at 21st Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it w
Read more →NXTCNextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - Multiple data readouts expected in 2022, including updates for all three clinical programs - Ends 2021 with cash positio
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results Md. - March 3, 2022 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to t
Read more →NXTCNextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCNextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting
BELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data i
Read more →NXTCNextCure to Present at The JMP Securities Hematology and Oncology Summit
BELTSVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCNextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCNextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting BELTSVILLE, Md.
NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting Md. - November 13, 2021 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering a
Read more →NXTCNextCure Reports Third Quarter 2021 Financial Results and Provides Business Update BELTSVILLE, Md.
NextCure Reports Third Quarter 2021 Financial Results and Provides Md. - November 4, 2021 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-
Read more →NXTCNextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting
BELTSVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new d
Read more →NXTCNextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021
BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the c
Read more →NXTCNextCure Announces Three New Members of its Scientific Advisory Board
BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appoin
Read more →NXTCNextCure Announces Publication of Preclinical Data for NC410
BELTSVILLE, Md., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the public
Read more →NXTCNextCure Announces New Appointments to its Board of Directors BELTSVILLE, Md.
Announces New Appointments to its Board of Directors BELTSVILLE, Md., October 4, 2021 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-rela
Read more →NXTC▲ +12.2%on this newsshared move
NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new d
Read more →NXTCNextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it w
Read more →NXTCNextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
BELTSVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it w
Read more →NXTCNextCure Reports Second Quarter 2021 Financial Results BELTSVILLE, Md.
Second Quarter 2021 Financial Results BELTSVILLE, Md. - August 5, 2021 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, t
Read more →NXTCNextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Pha
Read more →NXTCNextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of prec
Read more →NXTCNextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
BELTSVILLE, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinic
Read more →NXTCNextCure Reports First Quarter 2021 Financial Results
BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarte
Read more →NXTCNextCure to Present at the BofA Securities 2021 Virtual Health Care Conference
BELTSVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wil
Read more →NXTCNextCure to Present at the 7th Annual Truist Securities Life Sciences Summit
BELTSVILLE, Md., April 28, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it w
Read more →NXTCNextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinic
Read more →NXTCNextCure to Present at the 20th Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it w
Read more →NXTCNextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results BELTSVILLE, Md.
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Md. - March 4, 2021 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to t
Read more →NXTCNextCure to Host Virtual R&D Update Event on March 4, 2021
BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCDr. Han Myint Appointed as NextCure's Chief Medical Officer BELTSVILLE, Md.
Dr. Han Myint Appointed as NextCure's Chief Medical Officer BELTSVILLE, Md. - January 14, 2021 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other i
Read more →NXTCNextCure Provides Updates on NC318 Clinical Program
BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update o
Read more →NXTCNextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference
BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCNextCure, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
Investors with losses are encouraged to contact the firm before November 20, 2020; click here to submit trade information LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of NextCure, Inc.
Read more →NXTCNextCure Reports Third Quarter 2020 Financial Results
BELTSVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quart
Read more →NXTCNEXTCURE, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against NextCure, Inc.
LEAD PLAINTIFF DEADLINE IS NOVEMBER 20, 2020 NEW YORK, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) in the
Read more →NXTCNextCure Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
PHILADELPHIA, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) to determine whether the Company engaged in securities fraud or other unlawful
Read more →NXTCNextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors BELTSVILLE, Md.
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors BELTSVILLE, Md., September 14, 2020 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to
Read more →NXTCNextCure to Present at Morgan Stanley Virtual 18th Annual Global Healthcare Conference
BELTSVILLE, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it w
Read more →NXTCNextCure Reports Second Quarter 2020 Financial Results
BELTSVILLE, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quar
Read more →NXTCNextCure to Present at BTIG Virtual Biotechnology Conference
BELTSVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCNextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer BELTSVILLE, Md.
NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer BELTSVILLE, Md. - July 13, 2020 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discove
Read more →NXTCNextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors
BELTSVILLE, Md., July 07, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initia
Read more →NXTCNextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting
BELTSVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the present
Read more →NXTCNextCure Reports First Quarter 2020 Financial Results
BELTSVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarte
Read more →NXTCNextCure to Present at BofA Securities Virtual Health Care Conference
BELTSVILLE, Md., May 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wil
Read more →NXTCNextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic
BELTSVILLE, Md., April 13, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update
Read more →NXTCNextCure to Present at the 19th Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 08, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it w
Read more →NXTCNextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors BELTSVILLE, Md.
Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors BELTSVILLE, Md., March 30, 2020 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
Read more →NXTCNextCure Reports Fourth Quarter and Full Year 2019 Financial Results
BELTSVILLE, Md., March 12, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth qua
Read more →NXTCNextCure to Present at the 40th Annual Cowen Health Care Conference
BELTSVILLE, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCNextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference
BELTSVILLE, Md., Feb. 18, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it wi
Read more →NXTCNextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference
BELTSVILLE, Md., Jan. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the c
Read more →NXTCNextCure to Present at Piper Jaffray 31st Annual Healthcare Conference
BELTSVILLE, Md., Nov. 26, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the c
Read more →NXTCNextCure Announces Closing of Public Offering
BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closin
Read more →NXTCNextCure Announces Pricing of Public Offering of Common Stock
BELTSVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricin
Read more →NXTCNextCure Reports Third Quarter 2019 Financial Results
BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quart
Read more →NXTCNextCure Announces Proposed Public Offering of Common Stock
BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced a proposed
Read more →NXTCNextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial
NC318 was well tolerated Single agent activity observed in multiple tumor types, including a CR and a PR in NSCLC Initiated Phase 2 portion of the Phase 1/2 monotherapy trial and plans for a combo trial with standard of care chemotherapies BELTSVILLE, Md., Nov. 09, 2019 (GLOBE
Read more →NXTCNextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
BELTSVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and other immune-related diseases, today announced that the company will host and webca
Read more →NXTCNextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer Beltsville, Md.
NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer Beltsville, Md. October 2, 2019 NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat canc
Read more →NXTCNextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC
BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clini
Read more →NXTCNextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference
BELTSVILLE, Md., Sept. 03, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the
Read more →NXTCNextCure Reports Second Quarter 2019 Financial Results
BELTSVILLE, Md., Aug. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quar
Read more →NXTCNextCure Reports First Quarter 2019 Financial Results
BELTSVILLE, Md., June 10, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quart
Read more →NXTCNextCure Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BELTSVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing
Read more →NXTCNextCure Announces Pricing of Initial Public Offering of Common Stock
BELTSVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing
Read more →Competitive Position
How NXTC ranks across every disease it competes inCompetitive Position is a premium feature
See how NXTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial